This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
by Zacks Equity Research
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
by Zacks Equity Research
Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
by Zacks Equity Research
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) are on a downward trajectory since the ticker was dropped from the S&P SmallCap 600 index.
Apellis (APLS) Updates on Safety Concerns for Syfovre
by Zacks Equity Research
Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
by Zacks Equity Research
Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
by Zacks Equity Research
Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
by Zacks Equity Research
Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
by Zacks Equity Research
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
by Kinjel Shah
Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -8.94% and 65.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod
by Zacks Equity Research
Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.
Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?
by Zacks Equity Research
Emergent Biosolutions (EBS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.